Polarean Imaging plc (AIM:POLX)

London flag London · Delayed Price · Currency is GBP · Price in GBX
1.175
-0.050 (-4.08%)
Jun 13, 2025, 3:39 PM GMT+1
-23.20%
Market Cap 14.18M
Revenue (ttm) 2.47M
Net Income (ttm) -6.82M
Shares Out 1.21B
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 511,590
Average Volume 2,800,200
Open 1.225
Previous Close 1.225
Day's Range 1.145 - 1.250
52-Week Range 0.851 - 2.310
Beta -0.04
RSI 45.28
Earnings Date May 22, 2025

About Polarean Imaging

Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; and m... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2016
Employees 26
Stock Exchange London Stock Exchange AIM
Ticker Symbol POLX
Full Company Profile

Financial Performance

In 2024, Polarean Imaging's revenue was $3.09 million, an increase of 246.82% compared to the previous year's $890,933. Losses were -$8.54 million, -28.14% less than in 2023.

Financial numbers in USD Financial Statements

News

AIM Market Roundup: H&T, Polarean Imaging, Corcel

H&T Group, Polarean Imaging, Corcel are today's top risers, while Empyrean, Mirriad Advertising take the biggest fall on London's AIM market

4 weeks ago - The Armchair Trader

Polarean Raises $12.6 Million in Oversubscribed Financing Round to Accelerate XENOVIEW™ Commercialization and Strategic Growth Initiatives

DURHAM, NC and LONDON, June 20, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging...

1 year ago - GlobeNewsWire

FDA Approves Polarean's XENOVIEW™ (xenon Xe 129 hyperpolarized) for use with MRI for the Evaluation of Lung Ventilation

XENOVIEW represents the first and only hyperpolarized MRI contrast agent ● FDA approved indication includes both adolescents and adults representing a significant market opportunity XENOVIEW represent...

2 years ago - GlobeNewsWire